Trial | NCT00675207  Report issue

Title

Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs
Comparison of Brimonidine 0.15% Purite, Dorzolamide 2%, and Brinzolamide 1% as Adjunctive Therapy to Prostaglandin Analogs

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    120
The purpose of this study is to compare the efficacy of brimonidine Purite, dorzolamide, and brinzolamide in reducing intraocular pressure when added to prostaglandin analog therapy (bimatoprost, latanoprost, or travoprost) in patients with glaucoma or ocular hypertension.
Study Started
Jan 31
2006
Primary Completion
Jul 31
2007
Study Completion
Jul 31
2007
Last Update
May 08
2008
Estimate

Drug Brimonidine purite 0.15%

A single drop of brimonidine purite 0.15% ophthalmic solution administered topically in the eye 3 times daily.

  • Other names: Alphagan P 0.15%

Drug Dorzolamide 2%

A single drop of dorzolamide 2% ophthalmic solution administered topically in the eye 3 times daily.

  • Other names: Trusopt

Drug Brinzolamide 1%

A single drop of brinzolamide 1% ophthalmic solution administered topically in the eye 3 times daily.

  • Other names: Azopt

1 Active Comparator

Brimonidine purite 0.15%

2 Active Comparator

Dorzolamide 2%

3 Active Comparator

Brinzolamide 1%

Criteria 

Inclusion Criteria:

Diagnosis of primary open-angle glaucoma or ocular hypertension.
Must be over 40 years of age.
Intraocular pressure must be 18 mm Hg or higher after 6 weeks of treatment (run-in) with a prostaglandin analog (bimatoprost, latanoprost, or travoprost).

Exclusion Criteria:

History of angle closure or narrow angle.
Previous intraocular surgery.
Laser trabeculoplasty within 3 months prior to screening.
History of uveitis or intraocular inflammation.
Use of medications other than the study medications that are known to affect IOP (e.g., beta-blockers, steroids, or angiotensin II blockers) within 3 months of study entry or during the study.
Intolerance of or hypersensitivity to prostaglandin analogs, sulfonamides, alpha-agonists, or the preservative benzalkonium chloride.
Women of childbearing age who are pregnant or not using contraception.
No Results Posted